des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide、DesPro38Exendin-4(1-39)-Lys6-NH2、Lixisenatide (JAN/USAN/INN)

+ [11]

靶点

GLP-1R

作用方式

激动剂

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病

非在研适应症

急性冠状动脉综合征胃轻瘫帕金森病+ [1]

原研机构

Zealand Pharma A/S

在研机构

Sanofi-Aventis U.S. LLCSanofi KK

Sanofi Winthrop Industrie SA

+ [2]

非在研机构

Sanofi

赛诺菲（中国）投资有限公司Sanofi-Aventis Recherche & Développement SA

权益机构

Sanofi

Royalty Pharma Plc

Zealand Pharma A/S

最高研发阶段批准上市

首次获批日期

欧盟 (2013-01-31),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 25682

来源: *****

关联

项与利司那肽相关的临床试验

CTRI/2024/10/075222

/ Not yet recruiting临床4期

A Multicentre Phase IV single arm clinical trial to evaluate the safety and efficacy of a fixed ratio combination of Insulin Glargine and Lixisenatide in adult patients with Type 2 diabetes who are sub optimally controlled on oral anti-hyperglycemic drugs and/or basal Insulin/GLP-1 RA - iGlarLixi Phase 4 study in India

开始日期2024-10-28

申办/合作机构

Sanofi Healthcare India Pvt Ltd.

ChiCTR2400086382

/ Suspended临床4期IIT

Safety and efficacy of GLP-1RA combined with Banxia Xiexin Decoction in the treatment of type 2 diabetes

开始日期2024-07-15

申办/合作机构-

ChiCTR2300073482

/ CompletedN/AIIT

A real-world study of GLP-1RA in the treatment of diabetic nephropathy

开始日期2023-07-15

申办/合作机构-

100 项与利司那肽相关的临床结果

登录后查看更多信息

100 项与利司那肽相关的转化医学

登录后查看更多信息

100 项与利司那肽相关的专利（医药）

登录后查看更多信息

539

项与利司那肽相关的文献（医药）

2025-06-01·PHARMACOLOGICAL RESEARCH

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges

Review

作者: Popławska-Domaszewicz, Karolina ; Tan, Eng King ; Yi, Lingxiao ; Jankovic, Joseph ; Chaudhuri, Kallol Ray ; Zhou, Zhi Dong

Glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) belong to a class of compounds that reduce blood glucose and energy intake by simulating actions of endogenous incretin hormone GLP-1 after it is released by the gut following food consumption. They are used to treat type 2 diabetes mellitus (T2DM) and obesity and have systemic effects on various organs, including the brain, liver, pancreas, heart, and the gut. Patients with T2DM have a higher risk of developing neurodegenerative diseases (NDs), including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD), accompanied by more severe motor deficits and faster disease progression, suggesting dysregulation of insulin signaling in these diseases. Experimental studies have shown that GRA have protective effects to modulate neuroinflammation, oxidative stress, mitochondrial and autophagic functions, and protein misfolding. Hence the compounds have generated enormous interest as novel therapeutic agents against NDs. To date, clinical trials have shown that three GRA, exenatide, liraglutide and lixisenatide can improve motor deficits as an add-on therapy in PD patients and liraglutide can improve cognitive function in AD patients. The neuroprotective effects of these and other GRA, such as PT320 (a sustained-released exenatide) and semaglutide, are still under investigation. The dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists have been demonstrated to have beneficial effects in AD and PD mice models. Overall, GRA are highly promising novel drugs, but future clinical studies should identify which subsets of patients should be targeted as potential candidates for their symptomatic and/or neuroprotective benefits, investigate whether combinations with other classes of drugs can further augment their efficacy, and evaluate their long-term disease-modifying and adverse effects.

2025-06-01·DIABETES OBESITY & METABOLISM

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies

Review

作者: Hafidh, Khadija ; Mehta, Roopa ; Faraoun, Khadra ; Li, Xuan‐Tony ; Anaforoğlu, İnan ; Lauand, Felipe ; Home, Philip ; Djaballah, Khier ; Serafini, Paul ; Pourrahmat, Mir‐Masoud

Abstract:

Aims:

To estimate the relative treatment effect of iGlarLixi (a fixed‐ratio combination of insulin glargine 100 U/mL plus lixisenatide) versus premixed insulin IDegAsp (insulin degludec plus insulin aspart) in people with type 2 diabetes (T2D) who advanced from basal insulin to iGlarLixi or IDegAsp in non‐Asian studies.

Materials and Methods:

Randomized controlled trials (RCTs) were identified in a systematic review by searching Embase (including congress abstracts from 2021 to 2023), MEDLINE® and CENTRAL on 10 October 2023. Treatment outcomes from non‐Asian RCTs for people with T2D previously treated with basal insulin, who switched to iGlarLixi or IDegAsp, were compared using a network meta‐analysis (NMA). Data analysis was performed using R, version 4.0.2.

Results:

The NMA included four RCTs (N = 2535). The results of the NMA showed that iGlarLixi (n = 810) was associated with a significantly greater reduction in HbA1c versus IDegAsp (n = 454) (mean difference [MD]: −0.39 [95% credible interval, CrI: −0.58, −0.21] %‐units). iGlarLixi was also associated with a significantly greater likelihood of achieving an HbA1c of <7.0% (risk ratio: 1.42, 95% CrI: 1.18, 1.71). A greater reduction in postprandial glucose was observed with iGlarLixi versus IDegAsp (MD: −1.38 [95% CrI: −2.15, −0.63] mmol/L). A body weight benefit that favoured iGlarLixi versus IDegAsp was documented (MD: −1.54 [95% CrI: −2.26, −0.84] kg). Hypoglycaemia evaluation was inconclusive due to definitional differences between trials.

Conclusions:

Once‐daily iGlarLixi was associated with superior blood glucose control and body weight benefit compared with IDegAsp in insulin‐experienced populations with T2D in non‐Asian RCTs.

2025-06-01·NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders

Review

作者: Lam, Pak Ho ; Au, Hezekiah C T ; McIntyre, Roger S ; Lim, Poh Khuen

INTRODUCTION:

Glucagon-like Peptide-1 (GLP-1) and Glucagon-Like Peptide-1 receptor agonist (GLP-1 RA) administration has been associated with neuroprotective effects in neurodegenerative disorders. We conducted a comprehensive synthesis of known effects of GLP-1 and GLP-1 RAs on the cognitive, cellular, and molecular changes in neurodegenerative diseases.

METHODS:

We examined preclinical and clinical paradigms that investigated changes in neurodegenerative disease pathology following administration of GLP-1 and GLP-1 RAs. Relevant articles were retrieved through OVID (MedLine, Embase, AMED, PsychINFO, JBI EBP Database), PubMed, and Web of Science from database inception to September 27th, 2024. Primary studies investigating the aforementioned changes following GLP-1 and GLP-1 RA administration were retrieved for analysis (n = 62).

RESULTS:

GLP-1 and GLP-1 RAs (i.e. dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide) improved cognitive and motor function in neurodegenerative diseases in preclinical and clinical paradigms. Additionally, GLP-1 and GLP-1 RAs were associated with modulating changes in neuroinflammation, oxidative stress, and proliferative pathways.

DISCUSSION:

We observed that GLP-1 and GLP-1 RAs modulate molecular and cellular changes known to govern the phenomenology of neurodegenerative diseases. Future research should examine the interaction between signaling molecules, neuronal subpopulations, and cognitive effects affected by GLP-1 and GLP-1 RA administration.

119

项与利司那肽相关的新闻（医药）

2025-06-06

·FiercePharma

Diabetes patients who use GLP-1s may have a higher risk of serious eye disease: study

New findings come after a previous study linked GLP-1 use to a potential risk of developing nonarteritic anterior ischemic optic neuropathy. Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies.A recent study, published in JAMA Ophthalmology and conducted by University of Toronto researchers, found that diabetes patients who use GLP-1 drugs were twice as likely to develop neovascular age-related macular degeneration (nAMD) compared to their peers who don’t take the meds.AMD is a leading cause of irreversible blindness in older adults, affecting some 196 million people as of 2020, the study authors said. While atrophic AMD, also known as dry AMD, is more common, the neovascular form of the disease (the “wet” form) is more severe and often leads to rapid, permanent vision loss. The findings were collected after researchers evaluated the health data of 139,002 diabetes patients in Canada, all of whom were 66 years or older and either used a GLP-1 drug for more than six months or not at all. The patients were sorted into a 1:2 matched cohort, with researchers analyzing more than 46,000 patients who had used GLP-1s and more than 92,668 who hadn’t.Over three years of follow-up between 2020 and 2023, 0.2% (93 patients) of those in the GLP-1 user group were diagnosed with nAMD, as were 0.1% (88 patients) in the contrasting group.Of the GLP-1 group, 97.5% of patients were on Novo Nordisk’s popular diabetes and obesity GLP-1 semaglutide—sold as Wegovy, Ozempic and in oral form as Rybelsus—while 2.5% took Sanofi’s lixisenatide.As it turns out, the risk of developing nAMD was quite low regardless of GLP-1 usage, the study authors acknowledged. Still, the risk became even higher for those who were on GLP-1s the longest. Other risk nAMD risk factors noted in the study include advanced age and a history or cerebrovascular accident.“These findings expand upon the growing body of literature raising concerns regarding the potential ocular safety of systemic GLP-1 RA use in patients with diabetes,” researchers wrote, although the findings importantly speak to “associations, rather than cause and effect." Another previously noted ocular-related concern of the popular drugs is a potential risk factor for nonarteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that causes vision loss due to decreased blood supply to the optic nerve. After a study published in JAMA Ophthalmology last summer found that people taking Novo’s semaglutide for diabetes or weight loss were four to nearly eight times as likely to end up with NAION, the European Medicines Agency (EMA) took its own look at the possible safety risk.On June 6, the EMA’s safety committee recommended that the product information for semaglutide be updated to include NAION as a “very rare” side effect that could affect up to 1 in 10,000 people.The agency came to the conclusion after evaluating results from several large studies, and will now send its recommendation over to the Committee for Medicinal Products for Human Use (CHMP) before the European Commission makes its legally binding decision.

2025-05-31

·药时空

见微知著，一文盘点 GLP-1RA 心血管获益差异

动脉粥样硬化性心血管疾病（ASCVD）是 2 型糖尿病（T2DM）患者重要的伴发疾病，也是其致死和致残的主要原因[1]。据统计，每 3 位糖尿病患者中就有 1 位合并心血管疾病[2]。在我国，每 2 位糖尿病患者就有 1 位死于心脑血管事件[3]。自 2024 年以来，国内外权威指南重磅更新[2,4]，胰高血糖素样肽-1 受体激动剂（GLP-1RA）跃升为 T2DM 合并 ASCVD 患者的一线用药。目前，我国已上市的 GLP-1RA 药物近 10 种，涵盖短效制剂（贝那鲁肽、艾塞那肽、利司那肽），以及长效制剂（利拉鲁肽、艾塞那肽周制剂、洛塞那肽、司美格鲁肽片及注射液、度拉糖肽）[2]。然而，并非所有 GLP-1RA 药物都具备明确的心血管获益。大型心血管结局试验（CVOT）结果显示，GLP-1RA 药物在心血管保护方面并不具备类效应，且不同 GLP-1RA 在心血管保护方面也存在显著差异[5-6]，有的可显著降低全因死亡风险，有的则更侧重于卒中风险的干预。那么，在临床实践中应如何科学选择合适的 GLP-1RA？本文将系统梳理各类 GLP-1RA 的临床研究结果及指南推荐，为合并不同心血管疾病的 T2DM 提供诊疗方案参考。01异质性揭秘：GLP-1RA 的 CVOT 研究数据对比LEADER 研究[7]、REWIND 研究[8]及 SUSTAIN 6 研究[9]结果表明，对于伴有心血管疾病（CVD）或心血管高风险的 T2DM 患者，利拉鲁肽、度拉糖肽、司美格鲁肽（注射剂型）药物均较安慰剂显著降低 3P-MACE（非致死性心肌梗死、非致死卒中或心血管死亡的复合终点）风险，分别降低 13%、12%、26%，见表 1。尽管三种药物均达到了 3P-MACE 终点，但在具体事件获益方面存在差异：利拉鲁肽是目前三者中唯一显著降低心血管死亡风险的药物，度拉糖肽和司美格鲁肽（注射剂型）则无显著差异[7-9]。这一发现尤为关键，因为糖尿病患者的心血管死亡风险为非糖尿病人群的 2.1 倍[10]。我国糖尿病患者中 47.5% 的男性和 49.7% 的女性死于心血管疾病[3]。因此，利拉鲁肽在降低心血管死亡方面的独特优势，具有重要临床指导意义。利拉鲁肽虽在卒中风险方面有一定获益，但未达到统计学显著差异[7]；相比之下，司美格鲁肽降低卒中风险 39%，度拉糖肽降低 24%，司美格鲁肽显示出更强的卒中预防效果[8-9]。因此，2024 年发布的《2 型糖尿病患者卒中预防及血糖管理专家共识》[11]推荐将这两种药物用于卒中一级预防。三种药物在降低心肌梗死风险方面均显示一定获益，但无显著差异。02利拉鲁肽：独特作用机制发挥心血管保护如上所述，不同 GLP-1RA 对于心血管获益存在明显差异。其中，利拉鲁肽不仅可显著降低心血管死亡，还能减少非致死性心梗和卒中风险[7]。其显著的心血管保护效应，源于其独特的药理机制。研究显示，利拉鲁肽可通过直接与间接机制，协同发挥作用，为 T2DM 患者的心血管健康提供全方位支持[12-13]。图 1. 利拉鲁肽分别降低三个单独成分事件的风险JACC（IF = 12.9）改善心肌灌注，提高能量代谢T2DM 患者的心脏损伤与心肌血流减少和能量代谢异常密切相关[13]。2024 年发表于 JACC（IF = 12.9）的一项临床研究显示[13]，利拉鲁肽可通过减轻内皮细胞的内质网功能障碍以及恢复血管胰岛素敏感性，来改善 T2DM 患者的心肌灌注。研究结果显示，对于 T2DM 患者来说，与单纯减少胰岛素抵抗（IR）治疗策略相比（吡格列酮治疗），利拉鲁肽可显著增加应激心肌血流（1.62～2.08 mL/g/min，P = 0.01）和心肌灌注储备（2.40～2.90，P = 0.01），同时显著提高静息和负荷情况下心肌的磷酸肌酸与三磷酸腺苷浓度（PCr/ATP）比值（P < 0.01）及 6 分钟步行距离（488～521 m，P = 0.009）。以上提示利拉鲁肽在改善 T2DM 患者心肌功能，改善心肌灌注、能量代谢和运动耐量方面有显著效果。图 2. 利拉鲁肽 vs 吡格列酮引起的心肌变化注：A. 负荷心肌血流、B. 心肌灌注储备、C. 静息 PCr/ATP、D. 负荷 PCr/ATP减缓动脉粥样硬化与冠心病进展糖尿病患者因血液黏滞度增加，属于冠心病的高发人群，而利拉鲁肽在降低 2 型糖尿病患者血糖的同时，可改善心功能、免疫因子水平及血管微环境[12]。它能提高血管内皮生长因子（VEGF）和基质细胞衍生因子-1α（SDF-1α）的循环浓度，促进血管修复，减缓动脉粥样硬化进程[13]。此外，利拉鲁肽还可通过降低血糖、调节血脂代谢，进一步改善动脉粥样硬化[12]。改善急性心梗后心脏重构当 T2DM 患者发生心肌梗死后，在直接经皮冠状动脉介入治疗（PCI）及常规药物治疗的基础上加用利拉鲁肽，可以改善左心室重构，抑制炎症和氧化应激，使更多的心血管获益[12]。03指南推荐：临床个体化选择 GLP-1RA 治疗方案T2DM 患者主要的死亡原因是心血管疾病，其中 40% 归因于冠心病，15% 归因于心力衰竭，10% 归因于脑卒中。对于合并不同类型的心血管疾病情况，指南推荐治疗方案也有所不同。合并 ASCVD 及心血管危险因素2024 版 CDS 指南[2]和《冠心病合并 2 型糖尿病患者的血糖管理专家共识》[14]指出，推荐此类患者优先选用具有明确心血获益的降糖药物——部分 GLP-1RA（利拉鲁肽、司美格鲁肽和度拉糖肽）以及部分 SGLT2i（恩格列净、达格列净和卡格列净）。其中，利拉鲁肽可降低 CVD 死亡和全因死亡风险。2025 ADA 诊疗标准[3]同样强调，在这类患者中使用 GLP-1RA 可带来明确的心血管获益，并指出与 SGLT2i 联合使用可进一步减少心血管不良事件。心力衰竭2025 ADA 诊疗标准[3]指出，对于 T2DM 合并肥胖、射血分数保留的心力衰竭（HFpEF）患者，推荐使用已证明对减少 HF 相关症状、身体限制和运动能力的 GLP-1RA 治疗。合并卒中风险《2 型糖尿病患者卒中预防及血糖管理专家共识》[11]推荐对于存在卒中风险的 T2DM 患者使用司美格鲁肽、度拉糖肽作为卒中一级预防的降糖药物。合并急性冠脉综合征（ACS）《冠心病合并 2 型糖尿病患者血糖管理专家共识》[14]指出，对于病情稳定且无 GLP-1RA 禁忌的 ACS 患者，可在入院后给予 GLP-1RA 治疗，以优化血糖控制并改善心血管预后。结语综上所述，国内外指南均推荐，对于合并 ASCVD 及心血管高风险的 T2DM 患者，应早期、优先启用 GLP-1RA，以尽早获益，降低心血管死亡风险。然而，不同 GLP-1RA 药物对 T2DM 患者的心血管获益具有明显差异。其中，利拉鲁肽是目前唯一降低心血管死亡的 GLP-1RA，其通过直接保护心肌细胞，改善血管内皮功能，减缓动脉粥样硬化与冠心病进展等多重机制，实现对心血管系统的综合保护，司美格鲁肽和度拉糖肽则在卒中预防中表现突出，为患者点亮「心」的希望。✩ 本文仅供医疗卫生等专业人士参考参考文献[1]. 肖诚, 于淼. 胰高糖素样肽-1受体激动剂在2型糖尿病合并动脉粥样硬化性心血管疾病或高危风险人群中的可能机制及循证证据[J]. 中华糖尿病杂志, 2022, 14(12):1348-1354.[2]. 中华医学会糖尿病学分会. 中国糖尿病防治指南（2024版）[J]. 中华糖尿病杂志，2024，17(00):16-139.[3]. An Y, Zhang P, Wang J, etal. Cardiovascular and all‑cause mortality over a 23‑year period among Chinese with newly diagnosed diabetes in the Da Qing IGT and Diabetes Study[J]. Diabetes Care, 2015, 38(7):1365‑1371.[4]. ADA. Standards of Care in Diabetes-2025.[5]. 王静,胡天晓.胰高血糖素样肽-1受体激动剂心血管获益研究进展[J].浙江医学,2024,46(21):2241-2244+2259.[6]. 潘琦, 郭立新. 胰高糖素样肽-1受体激动剂的发展历程和临床应用进展 [J] . 中华糖尿病杂志, 2022, 14(12) : 1355-1363. DOI: 10.3760/cma.j.cn115791-20220802-00375 .[7]. Marso SP, Daniels GH, Brown‑Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311‑322.[8]. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‑blind, randomised placebo‑controlled trial[J]. Lancet, 2019, 394(10193):121‑130.[9]. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375(19):1834‑1844.[10]. Spitzer E, McFadden E, Vranckx P, et al. Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document[J]. JACC Cardiovasc Interv, 2019, 12(9):805-819.[11].《2型糖尿病患者卒中预防及血糖管理专家共识》编写委员会. 2型糖尿病患者卒中预防及血糖管理专家共识. 中华内科杂志，2024，63(07):649-659. DOI:10.3760/cma.j.cn112138-20231201-00356 [12]. 黄俊颖,管少迪,伍虹燕,等.利拉鲁肽的器官保护作用及研究进展[J].西南医科大学学报,2022,45(02):157-160.[13]. Chowdhary A, Thirunavukarasu S, Joseph T, Jex N, Kotha S, Giannoudi M, Procter H, Cash L, Akkaya S, Broadbent D, Xue H, Swoboda P, Valkovič L, Kellman P, Plein S, Rider OJ, Neubauer S, Greenwood JP, Levelt E. Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes. J Am Coll Cardiol. 2024 Aug 6;84(6):540-557. doi: 10.1016/j.jacc.2024.04.064 . PMID: 39084829; PMCID: PMC11296502.[14]. 刘靖,周翔海.冠心病合并2型糖尿病患者的血糖管理专家共识[J].中国循环杂志,2024,39(04):342-352.识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

临床结果

2025-05-29

·国际糖尿病idiabetes

道法自然！FRC双靶点，破解T2DM“双高”困境！

*本内容仅供医疗卫生专业人士阅读参考前言您的血糖管理跟上了吗？2型糖尿病（T2DM）患者的稳态控糖之旅犹如翻越万里长城，沿途布满了重重难关与挑战，每一步都考验着决心与智慧......FRC控糖小队再启新程！本期是“宁启新程·控糖有道——2025长城病例闯关赛”第四期，由天津医科大学总医院刘铭教授担任守关人，由天津医科大学总医院李宏智医生担任领队，带领FRC控糖小队来到了控糖挑战第四关紫荆关......（照例，文末互动哦~）他们能否稳稳闯关？队长李医生首先，我们治疗的根本目的是将血糖控制达标，以降低糖尿病相关并发症风险。患者之前应用多种OADs治疗，方案复杂，但空腹和餐后血糖均不理想，同时还会增加肝肾代谢负担和药物相互作用等风险。患者本身已有肝损害，而且在服用足量磺脲类促泌剂的情况下空腹C肽只有0.72 ng/ml，提示胰岛β细胞功能已受损。甘精利司一针双效，可以同时控制空腹及餐后血糖，更可贵的是其并不影响肝功能，这无疑是我们更好的选择。再有，患者之所以拒绝应用注射药物治疗，最主要的原因是对低血糖的恐惧。患者既往发生低血糖是因为脑膜瘤术后恢复期饮食少且不规律，没有及时调整胰岛素的剂量造成的。而甘精利司中的甘精胰岛素作为长效胰岛素类似物，其作用时间长，可覆盖全天基础血糖，同时其药效曲线基本平稳无峰，降低了低血糖风险。利司那肽可以通过降低食欲、延缓胃排空，改善胰岛素早相分泌等作用实现对餐后血糖的控制，而且其降糖作用是葡萄糖依赖性的，低血糖风险更小。研究表明，二者联用，低血糖风险与甘精胰岛素单药治疗相当，较基础-餐时胰岛素方案、预混胰岛素类似物和双胰岛素治疗方案的低血糖风险均更低[1-2]。第三，低血糖是可防可控的，只要患者积极配合，规律作息、饮食和运动定时定量、按时用药，就可有效降低低血糖风险。同时提醒患者住院期间如果出现头晕、心悸、出汗、乏力、强烈饥饿感等可疑低血糖症状时及时进行血糖检测，我们也会第一时间帮助患者确认低血糖并及时采取有效措施使其尽快摆脱低血糖状态。此外，我们还给出院患者贴心准备了方便实用的应急糖果包，嘱咐患者出院后还可以佩戴动态血糖监测设备，以便随时掌握自己的血糖状态和变化趋势，在低血糖发生前或低血糖早期及时加餐或补充葡萄糖，避免严重低血糖的发生。相信通过我们耐心细致的沟通，患者一定会扫除心头的阴霾，同意尝试甘精利司。Some days later根据FRC控糖小队的降糖方案，降糖效果到底如何呢？那么，FRC控糖小队在李医生的带领下能否顺利通关，拿到通关令牌？一起来看看守关人刘铭教授怎么说~守关人患者经多种OADs治疗，血糖仍然控制不佳，面临FPG与PPG双高。FRC控糖小队选用甘精利司联合OADs的治疗方案，损有余而补不足，取得了非常好的效果，可谓“药海战术遇瓶颈，双靶点一招破局，各项指标齐向好”，为临床这类患者的治疗提供了非常好的借鉴。从发病机制来看，FPG升高的主要原因是机体基础胰岛素的分泌不足，因而基础胰岛素在控制FPG上具有“先天优势”。引起PPG升高的原因多样，主要是胰岛素早相分泌受损，胃排空速率加快。甘精利司是由基础胰岛素（甘精胰岛素）和胰高血糖素样肽-1受体激动剂（GLP-1RA）（利司那肽)组成的复方制剂，一方面可通过补充基础胰岛素，解决FPG的问题；另一方面，利司那肽能够使患者的早相胰岛素分泌增加2.8倍（P＜0.001），晚相胰岛素分泌增加1.6倍（P＜0.001）[3]，同时利司那肽还可有效延缓胃排空达80%，从而可起强效控制PPG的效果[4]。一项网状荟萃分析，共纳入40项随机对照试验（RCTs），涵盖了包括替尔泊肽、甘精利司、德谷利拉、GLP-1RA+钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）、大剂量GLP-1RA（度拉糖肽3 mg 和司美格鲁肽4.5 mg及2 mg）等在内的以GLP-1RA为基础的治疗方案及其他常见注射治疗方案，旨在探索这些T2DM治疗方案的疗效和安全性。结果显示，不同降糖方案中，甘精利司对FPG、PPG的控制均最有效，尤其是对PPG的改善，较安慰剂差异达4.4 mmol/L[5]。因此，对于OADs治疗血糖控制不佳的患者，在起始注射治疗时可优先选用甘精利司，其不仅兼顾FPG与PPG控制，使患者血糖快速达标，而且可简化治疗方案，提高用药依从性，从而实现血糖长期稳定控制。最后，恭喜大家顺利通过本关授予稳态控糖之旅“紫荆关”通关令牌前路倒马关，血糖暗流涌动望与宁同行，稳扎稳打破难关“紫荆关”闯关互动扫描二维码进入签到并答题（连续集齐6期通关令牌，即可赢取学术好礼）参考文献：（上下滑动查看更多）[1]《基础胰岛素/胰升糖素样肽-1受体激动剂复方制剂用于治疗2型糖尿病的临床专家建议》编写委员会. 基础胰岛素/胰升糖素样肽-1受体激动剂复方制剂用于治疗2型糖尿病的临床专家建议. 中华内分泌代谢杂志，2023，39(08):645-650. DOI:10.3760/cma.j.cn311282-20230115-00027[2]Liu M, Gu W, Chen L, et al. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial. Diabetes Obes Metab. 2024 Sep;26(9):3791-3800. doi: 10.1111/dom.15724. Epub 2024 Jun 22. PMID: 38922731.[3]Becker RH, Stechl J, Msihid J, et al. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects. Diabetes Obes Metab. 2014 Sep;16(9):793-800. doi: 10.1111/dom.12278. Epub 2014 Mar 25. PMID: 24521245; PMCID: PMC4237545.[4]Becker RH, Stechl J, Steinstraesser A, et al. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects. Diabetes Metab Res Rev. 2015 Sep;31(6):610-8. doi: 10.1002/dmrr.2647. Epub 2015 Apr 23. PMID: 25773712; PMCID: PMC4744661.[5]Caruso I, Di Gioia L, Di Molfetta S, et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine. 2023 Sep 12;64:102181. doi: 10.1016/j.eclinm.2023.102181. PMID: 37719418; PMCID: PMC10500557.声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。MAT-CN-2509776最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

抗体药物偶联物

100 项与利司那肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09729	利司那肽	A10BJ03	DB09265

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	欧盟	Sanofi Winthrop Industrie SA	2013-01-31
2型糖尿病	冰岛	Sanofi Winthrop Industrie SA	2013-01-31
2型糖尿病	列支敦士登	Sanofi Winthrop Industrie SA	2013-01-31
2型糖尿病	挪威	Sanofi Winthrop Industrie SA	2013-01-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性冠状动脉综合征	临床3期	美国	Sanofi	2010-06-01
急性冠状动脉综合征	临床3期	中国	Sanofi	2010-06-01
急性冠状动脉综合征	临床3期	日本	Sanofi	2010-06-01
急性冠状动脉综合征	临床3期	阿根廷	Sanofi	2010-06-01
急性冠状动脉综合征	临床3期	澳大利亚	Sanofi	2010-06-01
急性冠状动脉综合征	临床3期	奥地利	Sanofi	2010-06-01
急性冠状动脉综合征	临床3期	白俄罗斯	Sanofi	2010-06-01
急性冠状动脉综合征	临床3期	比利时	Sanofi	2010-06-01
急性冠状动脉综合征	临床3期	巴西	Sanofi	2010-06-01
急性冠状动脉综合征	临床3期	保加利亚	Sanofi	2010-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03439943 (LIXIPARK, Pubmed \| N Engl J Med)	临床2期	帕金森病	156	Lixisenatide	願醖獵鑰願獵醖簾艱鏇(繭蓋繭積網壓齋夢艱繭) = Nausea occurred in 46% of participants receiving lixisenatide 衊繭繭餘鑰餘齋選觸簾 (簾製淵壓觸衊積獵醖餘 ) 更多	积极	2024-04-04
				Placebo
NCT03439943 (LIXIPARK, Literature) 人工标引	临床2期	帕金森病	156	Lixisenatide	糧鹽蓋網襯餘鹽顧憲製(選顧衊鹽選壓蓋鏇網襯) = 鹽鑰夢襯鹽簾獵夢艱壓鹽衊選製網選繭淵窪膚 (窪鏇艱夢廠壓願壓鬱顧 ) 更多	积极	2024-04-03
				Placebo	糧鹽蓋網襯餘鹽顧憲製(選顧衊鹽選壓蓋鏇網襯) = 簾醖願鹹繭餘壓選鬱築鹽衊選製網選繭淵窪膚 (窪鏇艱夢廠壓願壓鬱顧 ) 更多
NCT03798054 \| NCT03798080 (Pubmed)	临床3期	2型糖尿病	-	iGlarLixi	鹽齋簾鏇鏇網製憲鏇積(鏇構遞蓋餘構壓窪網觸): P-Value = 11.45	-	2023-03-30
				Glargine 100 U/mL
NCT03798080 (LixiLan-L-CN, Pubmed \| Diabetes Obes Metab) 人工标引	临床3期	2型糖尿病	426	iGlarLixi	積鑰餘鏇願淵鏇構醖鹽(廠窪獵顧築蓋糧廠襯淵) = 製獵壓餘範構顧廠遞遞糧獵憲積鏇構鏇鬱繭廠 (網襯艱簾鹽鏇積艱醖遞 ) 更多	优效	2022-06-28
				insulin glargine	積鑰餘鏇願淵鏇構醖鹽(廠窪獵顧築蓋糧廠襯淵) = 鹹鬱築餘壓糧壓製醖齋糧獵憲積鏇構鏇鬱繭廠 (網襯艱簾鹽鏇積艱醖遞 ) 更多
STAR.Ro (Pubmed) 人工标引	N/A	2型糖尿病	901	Lixisenatide+Insulin glargine	鏇網夢製遞鑰鏇鹹齋醖(構憲衊鑰醖鬱鬱繭淵構) = 鑰衊觸遞餘夢壓窪窪膚繭網鏇襯繭鏇顧蓋艱鏇 (願顧壓夢構製憲鑰觸淵, -1.4 ~ -1.2) 更多	积极	2022-05-27
NCT03798054 (LixiLan-O-AP, Pubmed \| Diabetes Obes Metab)	临床3期	2型糖尿病	878	iGlarLixi	構簾衊網鹽鏇築醖襯膚(範願壓齋鹽壓醖衊齋簾) = 遞積窪觸膚範淵蓋遞築憲艱製築鬱齋選糧製襯 (壓築觸顧簾簾顧遞蓋淵 ) 更多	积极	2022-04-19
				Insulin glargine 100 U/mL	構簾衊網鹽鏇築醖襯膚(範願壓齋鹽壓醖衊齋簾) = 餘簾襯艱窪鹽範廠選衊憲艱製築鬱齋選糧製襯 (壓築觸顧簾簾顧遞蓋淵 )
NCT02231658 (EASD2020)	临床1期	2型糖尿病	57	Lixisenatide	選鹽窪製製簾窪顧積網(蓋遞夢顧鏇網壓襯襯願) = 顧蓋壓製繭鏇製鑰構網簾衊衊窪餘鑰築餘簾壓 (築鑰鹹膚鏇獵願醖壓顧 ) 更多	积极	2020-09-24
				Liraglutide	選鹽窪製製簾窪顧積網(蓋遞夢顧鏇網壓襯襯願) = 選選鏇餘鹽鹽顧艱築淵簾衊衊窪餘鑰築餘簾壓 (築鑰鹹膚鏇獵願醖壓顧 )
NCT02231658 (Pubmed \| Diabetes Care)	临床1期	2型糖尿病	57	Lixisenatide	廠蓋觸衊遞築築鬱獵鏇(繭築襯製選築遞壓築齋) = 壓壓衊窪簾鬱顧製餘鑰鬱鹽鑰夢願簾憲製鬱願 (範衊壓鏇網襯膚襯鏇壓, -40.6, ~ 0.8) 更多	-	2020-07-09
				Liraglutide	齋鹹襯廠鑰鏇鑰夢製衊(願餘齋糧齋淵鏇簾範獵) = 襯淵簾衊鏇積壓夢壓積窪糧襯選膚範醖鑰壓窪 (繭廠遞繭鹽淵鏇齋獵網, 3 ~ 46)
NCT02640118 (Pubmed \| Diabetologia)	N/A	糖尿病	12	Lixisenatide	製製窪壓淵鏇構壓觸襯(醖願願遞憲繭鹹壓夢襯) = 範繭艱簾鬱獵鏇醖築願製夢鑰衊選鹽構選蓋壓 (憲艱築觸膚壓憲夢襯鏇 ) 更多	-	2020-07-01
				Placebo	製製窪壓淵鏇構壓觸襯(醖願願遞憲繭鹹壓夢襯) = 艱築衊窪築廠襯膚糧艱製夢鑰衊選鹽構選蓋壓 (憲艱築觸膚壓憲夢襯鏇 ) 更多
NCT02749890 (Pubmed \| Diabetes Care) 人工标引	临床3期	2型糖尿病	321	Insulin Glargine+Lixisenatide	醖顧構壓構範糧簾獵糧(齋膚築鹽憲衊齋遞鑰網) = 廠醖簾遞觸壓顧齋網鑰積廠鑰憲積窪蓋鹽簾範 (遞獵構選壓窪衊膚廠觸 ) 更多	优效	2020-06-01
				Lixisenatide	醖顧構壓構範糧簾獵糧(齋膚築鹽憲衊齋遞鑰網) = 鏇襯蓋憲選構獵網願鏇積廠鑰憲積窪蓋鹽簾範 (遞獵構選壓窪衊膚廠觸 ) 更多